Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116505 | 0.84 | GPR119 (0.41) | GPR119CDK7CDK13CDK12WNT3A | |
| SCHEMBL22358008 | 0.83 | ATR (0.43) | GPR119CDK7CDK13CDK12WNT3A | |
| SCHEMBL20117184 | 0.81 | GRM1 (0.48) | GPR119PDK4NAMPTGRM1GRM5 | |
| SCHEMBL30720958 | 0.81 | GRM1 (0.48) | GPR119PDK4NAMPTGRM1GRM5 | |
| SCHEMBL22358271 | 0.79 | PTGER3 (0.44) | GPR119 | |
| SCHEMBL22358017 | 0.78 | GPR119 (0.41) | GPR119CDK7CDK13CDK12WNT3A | |
| SCHEMBL29197647 | 0.76 | NAMPT (0.50) | CDK7CDK13CDK12WNT3APDK4 | |
| SCHEMBL30112338 | 0.76 | NAMPT (0.50) | CDK7CDK13CDK12WNT3APDK4 | |
| SCHEMBL15054200 | 0.75 | CCR4 (0.46) | CDK7CDK13CDK12PDK4NAMPT | |
| SCHEMBL15054202 | 0.75 | CCR4 (0.46) | CDK7CDK13CDK12PDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GPR119 2922/4885CDK7 2501/4885CDK13 2574/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | GPR119 2922/4885CDK7 2501/4885CDK13 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.